CDC Consolidates HPV Vaccine Recommendations

By Rob Goodier

September 03, 2014

NEW YORK (Reuters Heatlh) - The U.S. Centers for Disease Control and Prevention published consolidated guidelines on human papilloma virus (HPV) vaccination in the August 29 Morbidity and Mortality Weekly Report.

The CDC's Advisory Committee on Immunization Practices makes the following recommendations:

For children ages 11 or 12, girls should be vaccinated with either of the two vaccines available in the U.S., HPV4 or HPV2. Boys should be vaccinated with HPV4.

If they have been not vaccinated earlier, females ages 13 to 26 years should be vaccinated, and so should males ages 13 to 21 years. Males ages 22 to 26 may also be vaccinated if they have not before, according to the agency.

Other groups that should be vaccinated include men who have sex with other men and anybody with a condition that suppresses the immune system, such as an HIV infection.

The report brings together previously published recommendations into one document, but it does not add anything new, lead author Dr. Lauri Markowitz, of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, told Reuters Health by email.

The report also describes the vaccines and summarizes what is known about HPV and cancers.

Researchers have discovered more than 150 types of HPV, and the vaccines can protect against two types, 16 and 18, that are associated with 70% of cases of cervical cancer worldwide.

The HPV4 vaccine can also protect against types 6 and 11, which can cause low-grade cervical cell changes and genital warts.


MMWR 2014;63:1-30.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.